NCT01362257View on ClinicalTrials.gov

A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 29, 2011

Primary Completion Date

June 22, 2011

Study Completion Date

June 22, 2011

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Treatment Period 1 - IV dose of GSK573719

single dose of 65µg

DRUG

Treatment Period 2 - Oral dose of GSK573719

single dose of 1000µg

Trial Locations (1)

9471 GP

GSK Investigational Site, Zuidlaren

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY